Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice

Kasper Almholt, L.R. Lund, Jørgen Rygaard, Boye Schnack Nielsen, Keld Danø, John Rømer Nielsen, Morten Johnsen

125 Citations (Scopus)

Abstract

A prominent phenotype of plasmin deficiency in mice is reduced metastasis in the MMTV-PymT transgenic breast cancer model. Proteolytically active plasmin is generated from inactive plasminogen by one of 2 activators, uPA or tPA. We now find that uPA deficiency alone significantly reduces metastasis >7-fold in the MMTV-PymT model. We studied a cohort of 55 MMTV-PymT transgenic mice, either uPA-deficient or wild-type controls. Tumor incidence, latency, growth rate and final primary tumor burden were not significantly affected by uPA deficiency. In contrast, average lung metastasis volume was reduced from 1.58 mm3 in wild-type controls to 0.21 mm3 in uPA-deficient mice (p = 0.023). Tumor cell dissemination to brachial lymph nodes was also reduced from 53% (28/53) in wild-type controls to 31% (17/54) in uPA-deficient mice (p = 0.032). Mice without plasminogen display a severe pleiotropic phenotype. By comparison, spontaneous phenotypes are modest in uPA-deficient mice, probably because they still have active tPA. We show that metastasis is strongly and selectively decreased in uPA-deficient mice, suggesting that uPA-directed antimetastatic therapy would be efficacious and have limited side effects. © 2004 Wiley-Liss, Inc.
Original languageEnglish
JournalInternational Journal of Cancer
Volume113
Issue number4
Pages (from-to)525-32
ISSN0020-7136
DOIs
Publication statusPublished - 2005

Fingerprint

Dive into the research topics of 'Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice'. Together they form a unique fingerprint.

Cite this